Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Chronic Idiopathic Urticaria
NCT03111628Phase 4Completed
- Sponsor
- Johns Hopkins University
- Start
- Oct 2017
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by Johns Hopkins University. Primary endpoint: Time to 50% Decline in Clinical Symptoms Measured by the Urticaria Activity Score Seven Day (UAS7) at 12 weeks. Started Oct 2017; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NCT03111628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03111628.